• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Market
    News
    Stocks
    • Market
    • News
    • Stocks

    Cancer Drug Linked to Flesh-Eating Disease

    Investing News Network
    May. 02, 2013 11:32AM PST

    Canadian media is reporting today that the cancer drug Avastin has been linked to two cases of flesh-eating disease and one death.

    Canadian media is reporting today that the cancer drug Avastin has been linked to two cases of flesh-eating disease and one death. 

    The CBC reports that Health Canada, in conjunction with the drug’s manufacturer, Hoffman-La Roche Ltd., issued a warning following an earlier warning from the US Food and Drug Administration. The company admits that many more cases of necrotizing fasciitis occurred over the past 15 years, reports CBC:

    “Roche has conducted a comprehensive safety review that has identified 52 serious case reports of necrotizing fasciitis that occurred between November 1997 and September 2012, worldwide.”

    “Two of these reports occurred in Canada. A total of 17 of the global cases reported a fatal outcome, including one Canadian death.”

    Canadians will recognize the disease as the one that afflicted former Quebec premier Lucien Bouchard in the 1990s. In a warning posted on its website, Health Canada describes necrotizing fasciitis as “a severe, life-threatening bacterial infection of the skin and soft tissue” from which some patients have died.

    The FDA said in mid-March that cases have been mainly been seen in people who had wound-healing complications, gastrointestinal perforations or fistulas, according to CBC.

    Avastin is used either alone to treat brain cancer or in combination with chemotherapy to treat colon, rectal and lung cancer. The medication works by stopping the tumour from forming new blood vessels.

    life-science-investingcanada
    The Conversation (0)

    Go Deeper

    AI Powered

    April 2013 Stock Catalysts

    5 Movies About Energy You Need to Watch

    5 Movies About Energy You Need to Watch

    Latest News

    Juggernaut Announces Fully Funded 10,000 Meter Inaugural Drill Program on New District-Scale Gold Silver Copper Rich System at 100% Controlled Big One Property, Golden Triangle, B.C.

    Domestic Metals Appoints Dr. Peter Megaw as Technical Advisor to the Company

    First Hole Completed in Timmins Area Diamond Drill Program

    SAGA Metals Confirms Significant High-Grade Mineralization at Trapper North Releasing Additional Assays at Radar Critical Minerals Project in Labrador

    Westport Announces Start of Production at Two Key High-Pressure Controls and Systems Facilities

    More News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES